Aiming for a better understanding and management of cancer-related fatigue

Oncologist

Volumn 18, Issue 10, 2013, Pages 1135-1143

  Neefjes, Elisabeth C W ^a   van der Vorst, Maurice J D L ^a   Blauwhoff Buskermolen, Susanne ^a   Verheul, Henk M W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drug therapy; Fatigue; Methylphenidate; Modafinil; Neoplasms; Questionnaires

Indexed keywords

AMFEBUTAMONE; ANTIANEMIC AGENT; CARNITINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DONEPEZIL; ESTROGEN; ETANERCEPT; GROWTH HORMONE; HEMOGLOBIN; HYDROCORTISONE; INDOLEAMINE 2, 3 DIOXYGENASE; INFLIXIMAB; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; METHYLPHENIDATE; MODAFINIL; PAROXETINE; PLACEBO; PRASTERONE; PROGESTERONE; PROTIRELIN; SEROTONIN; SEROTONIN 1A RECEPTOR; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALTERNATIVE MEDICINE; ANEMIA; CANCER FATIGUE; COGNITIVE THERAPY; COMORBIDITY; DISEASE SEVERITY; DYSTHYMIA; EMOTIONAL STRESS; ERYTHROCYTE TRANSFUSION; EXERCISE; HUMAN; HYGIENE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; NUTRITIONAL DEFICIENCY; PAIN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; SUPRACHIASMATIC NUCLEUS; SYSTEMATIC REVIEW (TOPIC); COMPLICATION; FATIGUE; GENETICS; NEOPLASM; PATHOLOGY;

FATIGUE; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 84886045718     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0076     Document Type: Review

References (141)

1. Peuckmann-Post V, Elsner F, Krumm N et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2010;11:CD006788.
2. Jean-Pierre P, Morrow GR, Roscoe JA et al. A phase 3 randomized, placebo-controlled, doubleblind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy. Cancer 2010;116:3513-3520.
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Cancer Related Fatigue version 1.2013. Available at: http://www. nccn.org. Accessed February 21, 2013.
4. Cella D, Davis K, Breitbart W et al. Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001;19:3385-3391.
5. Cella DF, Peterman A, Passik S et al. Progress towardguidelines for themanagementof fatigue. Oncology 1998;62:369-377.
6. Kirkova J, Aktas A, Walsh D et al. Cancer symptom clusters: Clinical and research methodology. J Palliat Med 2011;14:1149-1166.
7. MorrowGR, Hickok JT, Roscoe JA et al. Differential effects of paroxetine on fatigue and depression: A randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003;21:4635-4641.
8. Roscoe JA, Morrow GR, Hickok JT et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005;89:243-249.
9. Radbruch L, Strasser F, Elsner F et al. Fatigue in palliative care patients-an EAPC approach. Palliat Med 2008;22:13-32.
10. Kroenke K, Wood DR, Mangelsdorff AD et al. Chronic fatigue in primary care: Prevalence, patient characteristics, and outcome. JAMA 1988;260: 929-934.
11. David A, Pelosi A, McDonald E et al. Tired, weak, or in need of rest: Fatigue among general practice attenders. BMJ 1990;301:1199-1202.
12. Barsevick AM, Cleeland CS, Manning DC et al. ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. J Pain Symptom Manage 2010;39:1086-1099.
13. Higginson IJ, Armes J, Krishnasamy M. Introduction in fatigue in cancer. In: Armes J, Krishnasamy M, Higginson IJ, eds. Fatigue in Cancer. Oxford, UK: Oxford University Press, 2004;17-21.
14. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: Relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000;8:175-179.
15. Roth AJ, Nelson C, Rosenfeld B et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 2010;116:5102-5110.
16. Hofman M, Ryan JL, Figueroa-Moseley CD et al. Cancer-related fatigue: The scale of the problem. The Oncologist 2007;12(suppl 1):4-10.
17. Mendoza TR, Wang XS, Cleeland CS et al. The rapid assessment of fatigue severity in cancer patients-use of the Brief Fatigue Inventory. Cancer 1999;85:1186-1196.
18. Kisiel-Sajewicz K, Davis MP, Siemionow V et al. Lack of muscle contractile property changes at the time of perceived physical exhaustion suggests central mechanisms contributing to early motor task failure in patients with cancer-related fatigue. J Pain Symptom Manage 2012;44:351-361.
19. Yavuzsen T, Davis MP, Ranganathan VK et al. Cancer-related fatigue: Central or peripheral? J Pain Symptom Manage 2009;38:587-596.
20. Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue: A practical guide for clinicians and researchers. J Psychosom Res 2004;56:157-170.
21. OkuyamaT, Akechi T, KugayaAet al. Development and validation of the cancer fatigue scale: A brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 2000;19:5-14.
22. Holley SK. Evaluating patient distress from cancer-related fatigue: An instrument development study. Oncol Nurs Forum 2000;27:1425-1431.
23. Knobel H, Loge JH, Brenne E et al. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med 2003;17: 664-672.
24. Shapiro CM, Flaingan M, Fleming JA et al. Development of an adjective checklist to measure five FACES of fatigue and sleepiness. Data from a national survey of insomniacs. J Psychosom Res 2002; 52:467-473.
25. Michielsen HJ, Vries de J, Heck van GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. J Psychosom Res 2003;54:345-352.
26. Iriarte J, Katsamakis G, CastrodeP. TheFatigue Descriptive Scale (FDS): A useful tool to evaluate fatigue in multiple sclerosis. MultScler1999;5:10-16.
27. Chalder T, Berelowitz G, Pawlikowska T et al. Development of a fatigue scale. J Psychosom Res 1993;37:147-153.
28. Krupp LB, LaRocca NG, Muir-Nash J et al. The Fatigue Severity Scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
29. Hann DM, Jacobsen PB, Azzarello LM et al. Measurement of fatigue in cancer patients: Development and validation of the Fatigue Symptom Inventory. Qual Life Res 1998;7:301-310.
30. Hann DM, Denniston MM, Baker F. Measurement of fatigue in cancer patients: Further validation of the Fatigue Symptom Inventory. Qual Life Res 2000;9:847-854.
31. Yellen SB, Cella DF, Webster K et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J PainSymptomManage 1997;13:63-74.
32. Monk T. A visual analogue scale to measure global vigor and affect. Psychiatry Res 1989;27:89-99.
33. Kirsh KL, Passik S, Holtsclaw E et al. I get tired for no reason: A single item screening for cancerrelated fatigue. J Pain Symptom Manage 2001;22: 931-937.
34. May J, Kline P. Problems in using an adjective checklist to measure fatigue. J Pers Individ Differ 1988;9:831-832.
35. Johansson B, Starmark A, Berglund P et al. A self-assessment questionnaire for mental fatigue and related symptoms after neurological disorders and injuries. Brain Inj 2010;24:2-12.
36. Kos D, Kerckhofs E, Carrea I et al. Evaluation of the Modified Fatigue Impact Scale in four different European countries. Mult Scler 2005;11:76-80.
37. Meek PM, Nail LM, Barsevick A et al. Psychometric testing of fatigue instruments for use with cancer patients. Nurs Res 2000;49:181-190.
38. Smets EMA, Garssen B, Bonke B et al. The Multidimensional Fatigue Inventory (MFI). Psychometric properties of an instrument to assess fatigue J Psychosom Res 1995;39:315-325.
39. Stein KD, Martin SC, Hann DM et al. A multidimensional measure of fatigue for use with cancer patients. Cancer Pract 1998;6:143-152.
40. Patient-Reported Outcomes Measurement Information System Fatigue Short Forms. Available at: http://www.nihpromis.org. Accessed July 25, 2011.
41. Pearson RG. Scale analysis of a fatigue checklist. J Appl Psychol 1957;41:186-191.
42. Piper BF, Lindsey A, Dodd MJ et al. Developmentofaninstrument tomeasurethe subjective dimension of fatigue. In: Funk S, Tournquist E, Champagne M, et al. eds. Key Aspects of Comfort: Management of Pain, Fatigue and Nausea. New York: Springer, 1989:199-208.
43. Ray C, Weir WRC, Philips S et al. Development of a measure of symptoms in chronic fatigue syndrome-the Profile of Fatigue Related Symptoms (PFRS). Psychol Health 1992;7:27-43.
44. Shacham S. A shortened version of the profile of mood states. J Pers Assess 1983;47:305-306.
45. Piper BF, Dibble SL, Dodd MJ et al. The Revised Piper Fatigue Scale: Psychometric evaluation in women with breast cancer. Oncol Nurs Forum 1998;25:677-684.
46. Rhoten D. Fatigue and the postsurgical patient. In: Norris C, ed. Concept Clarification in Nursing. Rockville, MD: Aspen Systems, 1982;277-300.
47. Hadzi-Pavlovic D, Hickie IB, Wilson AJ et al. Screening for prolonged fatigue syndromes: Validation of the SOFA scale. Soc Psychiatry Psychiatr Epidemiol 2000;35:471-479.
48. Schwartz AL. The Schwartz Cancer Fatigue Scale: Testing reliability and validity. Oncol Nurs Forum 1998;25:711-717.
49. Schwartz A, Meek P. Additional construct validity of the Schwartz Cancer Fatigue Scale. J Nurs Meas 1999;7:35-45.
50. Brown LF, Kroenke K, Theobald DE et al. Comparison of SF-36 vitality scale and Fatigue Symptom Inventory in assessing cancer-related fatigue. Support Care Cancer 2011;19:1255-1259.
51. Yang CM, Wu CH. The Situational Fatigue Scale: A different approach to measuring fatigue. Qual Life Res 2005;14:1357-1362.
52. Glaus A. Assessment of fatigue in cancer and non-cancer patients and in healthy individuals. Support Care Cancer 1993;1:305-315.
53. Wu HS, Wyrwich KW, McSweeney M. Assessing fatigue in persons with cancer: Further validation of theWuCancer Fatigue Scale. J PainSymptom Manage 2006;32:255-265.
54. Seyidova-Khoshknabi D, Davis MP, Walsh D. Review article: A systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care 2011;28:119-129.
55. Cella D, Viswanathan HN, Hays RD et al. Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer 2008;113:1480-1488.
56. Hinds PS, Hockenberry M, Tong X et al. Validity and reliability of a new instrument to measure cancer-related fatigue in adolescents. J Pain Symptom Manage 2007;34:607-618.
57. MintonO, Stone PC. Asystematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 2009;20:17-25.
58. Ryan JL, Carroll JK, Ryan EP et al. Mechanisms of cancer-related fatigue. The Oncologist 2007; 12(suppl 1):22-34.
59. Barsevick A, Frost M, Zwinderman A et al. I'm so tired: Biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 2010;19:1419-1427.
60. Seruga B, Zhang H, Bernstein LJ et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008;8:887-899.
61. Segerstrom SC, Miller GE. Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry. Psychol Bull 2004;130: 601-630.
62. Fontes-Oliveira CC, Busquets S, ToledoMet al. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: Altered energetic efficiency? Biochim Biophys Acta 2013;1830:2770-2778.
63. Agteresch HJ, Dagnelie PC, van der Gaast A et al. Randomized clinical trial of adenosine 5-triphosphate in patients with advanced non-smallcell lung cancer. J Natl Cancer Inst 2000;92:321-328.
64. Beijer S, Hupperets PS, van den Borne BE et al. Randomized clinical trial on the effects of adenosine 5-triphosphate infusions on quality of life, functional status, and fatigue in preterminal cancer patients. J Pain Symptom Manage 2010;40:520-530.
65. Capuron L, Pagnoni G, Demetrashvili MF et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-therapy. Neuropsychopharmacol 2007;32:2384-2392.
66. Wichmann T, DeLong MR. Oscillations in the basal ganglia. Nature 1999;400:621-622.
67. Tanaka H, MaeshimaS, Shigekawa Y et al. Neuropsychological impairment and decreased regional cerebral blood flow by interferon treatment in patients with chronic hepatitis: A preliminary study. Clin Exp Med 2006;6:124-128.
68. Alexander S, MintonO, AndrewsPet al. Acomparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome Eur J Cancer 2009;45:384-392.
69. Mormont MC, Lévi F. Circadian-system alterations during cancer processes:Areview. Int J Cancer 1997;70:241-247.
70. Rich TA. Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis. J Support Oncol 2007;5:167-174.
71. Bower JE, Ganz PA, IrwinMRet al. Fatigue and gene expression in human leukocytes: Increased NF-B and increased glucocorticoid signalling in breast cancer survivors with persistent fatigue. Brain Behav Immune 2011;25:147-150.
72. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-142.
73. Miller AH, Ancoli-Israel S, Bower JE et al. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008;26:971-982.
74. Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 2005; 67:277-280.
75. Bower JE, Ganz PA, Aziz N et al. Fatigue and pro-inflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64:604-611.
76. Jager A, Sleijfer S, Rijt van der CCD. The pathogenesis of cancer related fatigue: Could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 2008;44:175-181.
77. Shafqat A, Einhorn LH, HannaNet al. Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol 2005;16:1545-1550.
78. Gutstein HB. The biologic basis of fatigue. Cancer 2001;92(suppl 6):1678-1683.
79. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005;14:166-174.
80. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer 2001;92(suppl 6):1684-1688.
81. Collado-Hidalgo A, Bower JE, Ganz PA et al. Cytokine gene polymorphisms and fatigue in breast cancer survivors: Early findings. Brain BehavImmun 2008;22:1197-1200.
82. BowerJE, Ganz PA, IrwinMRet al. Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol 2013;31:1656-1662.
83. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Cancerand chemotherapy-induced anemia version 1.2013. Available at: http://www.nccn.org. Accessed May 19, 2013.
84. Mercante S, Ferrera P, Villari P et al. Effects of red blood cell transfusion on anemia-related symptoms in patients with cancer. J Palliat Med 2009;12: 60-63.
85. MockV. Evidence-basedtreatmentfor cancerrelated fatigue. J Natl Cancer Inst Monogr 2004;32: 112-118.
86. Schmitz KH, Holtzman J, Courneya KS et al. Controlled physical activity trials in cancer survivors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2005;14:1588-1595.
87. Galvao DA, Newton RU. Review of exercise intervention studies in cancer patients. J Clin Oncol 2005;23:899-909.
88. Richardson A, Ream EK. Self-care behaviors initiated by chemotherapy patients in response to fatigue. Int J Nurs Stud 1997;34:35-43.
89. Graydon JE, Bubela N, Irvine D et al. Fatiguereducing strategiesusedbypatients receiving treatment for cancer. Cancer Nurs 1995;18:23-28.
90. Dy SM, Apostol CC. Evidence-based approaches to other symptoms in advanced cancer. Cancer J 2010;16:507-513.
91. BergerAM. Updateonthe state of the science: Sleep-wake disturbances in adult patients with cancer. Oncol Nurs Forum 2009;36:E165-E177.
92. Schutte-Rodin S, Broch L, Buysse D et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin SleepMed2008;4: 487-504.
93. Goedendorp MM, Gielissen MF, Verhagen CA et al. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 2009:1;CD006953.
94. Arnold M, Taylor NF. Does exercise reduce cancer-related fatigue in hospitalized oncology patients? A systematic review. Onkologie 2010;33: 625-630.
95. Dimeo FC, Tilmann MH, Bertz H et al. Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer 1997;79: 1717-1722.
96. Dimeo FC. Effects of exercise on cancer-related fatigue. Cancer 2001;92:1689-1693.
97. Mock V, Dow KH, Meares CJ et al. Gage I: Effects of exercise on fatigue, physical functioning and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 1997;24:991-1000.
98. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Sys Rev 2012;11:CD006145.
99. Knols R, Aaronson NK, Uebelhart D et al. Physical exercise in cancer patients during and after medical treatment: A systematic review of randomised and controlled trials. J Clin Oncol 2005;23: 3830-3842.
100. Oldervoll LM, Kaasa S, Hjermstad MJ et al. Physical exercise results in the improved subjective well-being of a few or is effective rehabilitation for all cancer patients? Eur J Cancer 2004;40:951-962.
101. van Waart H, Stuiver MM, van Harten WH et al. Design of the physical exercise during adjuvant chemotherapy effectiveness study (PACES): A randomized controlled trial to evaluate effectiveness and cost-effectiveness of physical exercise in improving physical fitness and reducing fatigue. BMC Cancer 2010;10:673-683.
102. Morrow GR, Shelke AR, Roscoe JA et al. Management of cancer-related fatigue. Cancer Invest 2005;23:229-239.
103. CullumJL, WojciechowskiAE, PelletierGet al. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004;49: 139-144.
104. Cruciani RA, Dvorkin E, Homel P et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue and carnitine deficiency:Aphase I/II study. J Pain Symptom Manage 2006;32:551-559.
105. Auret KA, Schug SA, Bremner AP et al. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manage 2009;37:613-621.
106. Butler JM, Case LD, Atkins J et al. A phase III, double-blind, placebo-controlled, prospective, randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007;69:1496-1501.
107. Mar Fan HG, Clemons M, Xu W et al. A randomised placebo-controlled double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008;16:577-583.
108. Bruera E, Ostael B, Valero V et al. Donepezil for cancer fatigue:Adouble-blind, randomized, placebo-controlled trial. J Clin Oncol 2007;25:3475-3481.
109. Monk JP, Philips G, Waite R et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy. J Clin Oncol 2006;24:1852-1859.
110. Tookman AJ, Jones CL, Witte de M et al. Fatigue in patients withadvancedcancer:Apilot study of an intervention with infliximab. Support Care Cancer 2008;16:1131-1140.
111. Sugawara Y, Akechi T, Shima Y et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: A preliminary study. Palliat Med 2002;16: 261-263.
112. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients withmelanoma:A pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002;7:E85-E90.
113. Bruera E, Driver L, Barnes EA et al. Patientcontrolled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report. J Clin Oncol 2003;21:4439-4443.
114. Bruera E, Valero V, Driver L et al. Patient-controlled methylphenidate for cancer fatigue: A double-blindrandomizedplacebo-controlled trial. J Clin Oncol 2006;24:2073-2078.
115. Johnson RL, Block I, Gold MA et al. Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. Psychooncology 2010;19: 955-958.
116. Spathis A, Dhillan R, BoodenDet al. Modafinil for the treatment of fatigue in lung cancer: A pilot study. Palliat Med 2009;23:325-331.
117. Kamath J, Yarbrough GG, Prange AJ et al. Thyrotropin-releasing hormone can relieve cancerrelated fatigue: Hypothesis and preliminary observations. J Int Med Res 2009;37:1152-1157.
118. Cruciani RA, Zhang JJ, Manola J et al. L-carnitine supplementation for the management of fatigue in patients with cancer: An eastern cooperativeoncologygroupphaseIII, randomized, doubleblind, placebo-controlled trial. J Clin Oncol 2012;30: 3864-3869.
119. Minton O, Richardson A, SharpeMet al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 2010;9: CD006704.
120. Moraska AR, Sood A, Shaker R et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancerrelated fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 2010;28: 3673-3679.
121. Bruera E, Yennurajalingam S, Palmer JL et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: A randomized, placebo-controlled, phase II trial. J Clin Oncol 2013;31:2421-2427.
122. Lower EE, Fleishman S, Cooper A et al. Efficay of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: A randomized clinical trial. J Pain Symptom Manage 2009; 38:650-662.
123. Bruera E, Roca E, Cedaro L et al. Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep 1985;69:751-754.
124. TannockI, GospodarowiczM, MeakinWet al. Treatment of metastatic prostatic cancer with lowdose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7:590-597.
125. Hardy JR, Rees E, Ling J et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med 2001;15:3-8.
126. Yennurajalingam S, Frisbee-Hume S, Palmer JL et al. Reduction of Cancer-Related Fatigue with Dexamethasone: A double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013;31:3076-3082.
127. Clark J, Cunningham M, McMillan S et al. Sleep-wake disturbances in people with cancer part II: Evaluating the evidence for clinical decision making. Oncol Nurs Forum 2004;31:747-771.
128. Lissoni P, Tancini G, Barni Set al. Treatmentof cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer 1997;5:126-129.
129. Lissoni P, Barni S, MandalaMet al. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer 1999;35:1688-1692.
130. Lissoni P, ChilelliM, Villa Set al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J Pineal Res 2003;35:12-15.
131. Lissoni P, Paolorossi F, ArdizzoiaAet al. Arandomized study of chemotherapy with cisplatin plus etopside versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 1997;23:15-19.
132. Lissoni P. Biochemotherapy with immunomodulating pinealhormonesother than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent. Pathol Biol 2007;55:198-200.
133. Burks TF. New agents for the treatment of cancer-related fatigue. Cancer 2001;92(suppl 6): 1714-1718.
134. Brzoska T, KaldenDH, Scholzen Tet al. Molecular basis of the MSH/IL-1 antagonism. Ann N Y Acad Sci 1999;885:230-238.
135. Qi F, Li A, Inagaki Y, Gao J et al. Chinese herbal medicines as adjuvant treatment during chemo-or radio-therapy for cancer. Biosci Trends 2010;4: 297-307.
136. Jeong JS, Ryu BH, Kim JS et al. Bojungikki-tang for cancer-related fatigue: A pilot randomized clinical trial. Itegr Cancer Ther 2010;9:331-338.
137. Barton DL, Soori GS, Bauer BA et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue:Arandomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 2010;18:179-187.
138. Elam JL, Carpenter JS, Shu XO et al. Methodological issues in the investigation of ginseng as an intervention for fatigue. Clin Nurse Spec 2006;20: 183-189.
139. Posadzki P, MoonTW, Choi TY et al. Acupuncture for cancer-related fatigue:Asystematic review of randomized clinical trials. Support Care Cancer 10.1007/s00520-013-1765-z.
140. Molassiotis A, Bardy J, Finnegan-John J et al. Acupuncture for cancer-related fatigue in patients with breast cancer: A pragmatic randomized controlled trial. J Clin Oncol 2012;30:4470-4476.
141. Buffart LM, van Uffelen JGZ, Riphagen II et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. BMC Cancer 2012;12:559-580.